Company intelligence / Profile preview

digiProps

Amsterdam, North Holland, Netherlandsdigiprops.co.za ↗

Ownership: Private
Development stage: Other

Overview

Digi.Bio offers a single-cell profiling platform that enables real-time measurement of individual cell fate and performance in response to various therapies. The system provides high-content data on cytotoxicity, motility, cell-cell interactions, and phenotypic responses. It accelerates the development of new therapies by allowing precise comparison across conditions with automated digital microfluidics. No clinical trial results are reported as the company provides enabling technology rather than developing therapeutics directly[1].

Modalities: Cell therapyMonoclonal antibodySmall molecule
Industry: Drug Discovery Services

Beyond the preview

Go deeper on digiProps.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on digiProps.

Explore the full profile